Market news

Personalis shareholders remain exposed to downside in TEM shares while having limited ability to benefit from further TEM appreciation above $48.42. Learn more about PSNL stock here.

Tempus AI, Inc. (NASDAQ:TEM) rallied following a melanoma breakthrough reported by Moderna and Merck. The companies said their Phase 3 INTerpath-001 trial met its recurrence-free survival endpoint for the personalized cancer therapy intismeran autogene, also known as V940, combined with Keytruda. Detailed trial data remain pending. The read-through came from Personalis, which has supported the […]

Personalis (PSNL) has demonstrated exceptional momentum, gaining nearly 250% over the past year. Shares recently set a new 3-year high. PSNL stock maintains a 100% “Buy” technical opinion from Barchart. Despite strong price appreciation, PSNL remains unprofitable and highly speculative, with mixed analyst sentiment and significant short interest. Today’s Featured...

Tempus AI, Inc. made a timely move to acquire the Personalis cancer monitoring tests to advance AI-driven precision medicine. Learn why TEM stock is a strong buy.

In recent days, investors have reacted to phase 3 INTerpath-001 trial results showing a customized mRNA-based melanoma treatment improved recurrence-free survival, while also focusing on Tempus AI’s pending US$1.50 billion acquisition of Personalis Inc. as a move deeper into cancer genomics. Together, the trial success and acquisition plan highlight how Tempus AI is tying advanced mRNA oncology research to its broader precision medicine and data-driven cancer testing ambitions. We’ll now...

BTIG analyst Mark Massaro raised the firm’s price target on Tempus AI to $80 from $70 and kept a Buy rating.

Tempus AI wrote a $1.5 billion check for a genomics company most investors had never heard of, and one blockbuster clinical trial announcement just changed everything about how that deal looks.

Personalis (PSNL) delivered earnings and revenue surprises of -20.00% and +30.21%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

FREMONT, Calif., August 04, 2026--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the second quarter ended June 30, 2026, and highlighted recent business accomplishments.

In the past week, Tempus AI, Inc. reported second-quarter 2026 results showing revenue of US$382.49 million and a swing from a net loss of US$42.84 million a year ago to net income of US$5.64 million, while also raising its full-year 2026 revenue outlook to between US$1.60 billion and US$1.61 billion. Alongside this performance, Tempus AI advanced its oncology and data ambitions through the planned acquisition of Personalis and highlighted growing diagnostics volume and new data...

Tempus AI’s Personalis deal puts acquisition price and growth bets in focus Tempus AI (TEM) has moved to acquire cancer testing company Personalis in a roughly $1.5 billion all stock deal, immediately putting the spotlight on valuation, integration risk, and long term growth assumptions. The agreement would fold Personalis’ minimal residual disease, or MRD, testing into Tempus AI’s precision oncology and data platform. The combined business would target a cancer monitoring market estimated at...

Tempus AI acquires Personalis for $1.5B to target the $20B MRD cancer monitoring market. Get full deal details and analysis.

Under the deal, Personalis’ minimal residual disease (MRD) test will be integrated into Tempus’ broader oncology portfolio.

Tempus AI (NasdaqGS:TEM) agreed to acquire cancer monitoring company Personalis in a deal valued at about US$1.5b. The transaction is focused on expanding Tempus AI's presence in minimal residual disease (MRD) testing and precision oncology. The company plans to combine Personalis' MRD technology with its existing AI driven precision oncology platform. For investors following Tempus AI, this deal highlights how central MRD testing and precision oncology have become in cancer care. Tempus AI...

The deal, structured as an all-stock transaction, gives Tempus control of Personalis' NeXT Personal cancer detection test

Tempus AI (NASDAQ:TEM) will acquire Personalis (NASDAQ:PNSL) in a stock deal valued at $1.5 billion, expanding its reach in the market for tests that monitor cancer recurrence after treatment. Personalis shareholders will receive $16.25 per share, a 6% premium to Friday's closing price and a...

Tempus AI (NASDAQ:TEM) executives said the company’s planned acquisition of Personalis is intended to strengthen its position in minimal residual disease, or MRD, testing, while expanding its biopharma data and profiling capabilities. On a call with analysts, Tempus said it agreed to acquire all ou

Tempus AI (TEM) agreed to acquire cancer test maker Personalis (PSNL) in a $1.5 billion deal that Ne

Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.

CHICAGO, July 20, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that it has entered into a definitive agreement to acquire Personalis, Inc. (NASDAQ: PSNL). The acquisition will expand Tempus' capabilities in minimal residual disease (MRD) and enhance its ability to support patients from diagnosis and treatment selection, to recurrence and monitoring.

The brokerage said the acquisition strengthens Tempus AI’s precision oncology business, though near-term financials are less compelling.

Tempus AI (TEM) has agreed to acquire Personalis (PSNL) in a deal with a total enterprise value of $

Tempus will pay a 5.6% premium to integrate Personalis' cancer-testing platform into its AI-enabled oncology business.